Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
APG777 · 4 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| APG777 - Long Term Extension Treatment - 12 Weeks | EXPERIMENTAL | Participants who achieve EASI 75 or a vIGA-AD (0, 1) at the end of the Parent Study Treatment Period, and who did not use topical rescue medication during the Parent Study will maintain the same dose regimen (dose and frequency of injections) from the Maintenance Period of the Parent Study (APG777-201). |
| APG777 - Long Term Extension Treatment - 24 Weeks | EXPERIMENTAL | Participants who achieve EASI 75 or a vIGA-AD (0, 1) at the end of the Parent Study Treatment Period, and who did not use topical rescue medication during the Parent Study, will maintain the same dose regimen (dose and frequency of injections) from the Maintenance Period of the Parent Study (APG777-201). |
| APG777 - Open Label Escape Arm | EXPERIMENTAL | Participants who do not achieve EASI 75 or a vIGA-AD (0, 1) at the end of the Parent Study Treatment Period, or who used topical rescue medication during the Parent Study, will be assigned to the open-label Escape Arm and will receive APG777 per protocol defined dosing regimen. |
| Part A: Induction Period: APG777 | EXPERIMENTAL | Participants will receive APG777 per protocol defined dosing regimen |
| Part A: Induction Period: Placebo | PLACEBO_COMPARATOR | Participants will receive matching Placebo injections per protocol defined dosing regimen |
| Part A: Maintenance Period: APG777 | EXPERIMENTAL | Participants will receive 1 of 2 maintenance regimens of APG777 per protocol defined dosing regimen |
| Part B: Induction Period: APG777 | EXPERIMENTAL | Participants will receive APG777 in 1 of 3 regimens per protocol defined dosing regimen |
| Part B: Induction Period: Placebo | PLACEBO_COMPARATOR | Participants will receive matching placebo injections per protocol defined dosing regimen |
| Part B: Maintenance Period: APG777 | EXPERIMENTAL | Participants will receive APG777 per protocol defined dosing regimen |
| APG777 + APG990 | EXPERIMENTAL | Participants will receive protocol specified combination dose of APG777 + APG990 |
| Dupilumab | ACTIVE_COMPARATOR | Participants will receive protocol specified dose of Dupilumab |
| APG777 | EXPERIMENTAL | Participants will receive protocol specified dose of APG7777 |
| Placebo | PLACEBO_COMPARATOR | Participants will receive matching placebo |
| Name | Type | Description |
|---|---|---|
| APG777 | DRUG | APG777 subcutaneous injection |
| Placebo | DRUG | Matching placebo subcutaneous injection |
| APG990 | DRUG | SC injection |
| Dupilumab | DRUG | SC injection |
Inclusion Criteria: * Participants who have completed the Treatment Period in a prior APG777 study and were, in the Investigator's opinion, compliant with the study protocol * Participants who, in the Investigator's opinion, would benefit from long-term treatment with APG777 * Use the same non-pres...
Top 20 of 25 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 9 | PHASE3 | Upadacitinib, corticosteroids |
| Pfizer Inc. | PFE | 11 | PHASE3 | Abrocitinib |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Lebrikizumab, Corticosteroid |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | Dupilumab |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib, Vehicle |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof, 1%, Vehicle |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-914 |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Sunshine Biopharma Incorporated | SBFM | 2 | PHASE3 | 611 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE1 | ARQ-234 |
APG777 is an investigational small molecule being developed for asthma and atopic dermatitis. It is currently in clinical trials for these conditions, including studies in adults with atopic dermatitis and asthma. The drug is not yet approved and remains in clinical development.
APG777 is being developed by Apogee Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol APGE. The company is conducting clinical trials to evaluate the drug's safety and efficacy in atopic dermatitis and asthma.
APG777 is in Phase 1 and Phase 2 clinical trials. It is an investigational drug, meaning it has not been approved by regulatory authorities. The trials include Phase 1 studies for safety and pharmacokinetics and Phase 2 studies for efficacy in atopic dermatitis.
APG777 is being studied in several clinical trials, including NCT06395948 and NCT07003425 for atopic dermatitis, NCT06920901 for asthma, and NCT07027527 for atopic dermatitis in combination with APG990. These trials are active and recruiting or not yet recruiting participants.
No, APG777 is not the same as APG990. APG777 is a separate investigational drug being studied alone and in combination with APG990 in a clinical trial for moderate-to-severe atopic dermatitis. The two drugs are distinct assets developed by Apogee Therapeutics.